Status:
RECRUITING
Brexpiprazole in Alcohol Use Disorder
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Alcohol Use Disorder
Eligibility:
All Genders
21-65 years
Phase:
PHASE2
Brief Summary
Few medications are currently Food \& Drug Administration (FDA)-approved for the treatment of Alcohol Use Disorder (AUD), and those that are have, on average, modest effects on drinking. "Precision me...
Detailed Description
The overarching hypothesis of this study is that brexpiprazole (BREX) (2 or 4 mg/day), relative to placebo, will reduce alcohol consumption and modulate the neural substrates of moderate-severe Alcoho...
Eligibility Criteria
Inclusion
- Ages 21-65.
- Meet DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnostic criteria for AUD, as assessed by the Structured Clinical Interview for DSM-5 (SCID-5).
- Currently not engaged in, and does not want treatment for, AUD.
- Currently not taking any medication for AUD.
- Able to read and understand questionnaires and informed consent.
- Lives within 50 miles of the study site.
- Physically healthy with no history of significant medical illness.
- Negative urine drug screen (UDS) for all substances of abuse prior to taking the first dose of medication.
- Please contact clinical site for additional inclusion criteria.
Exclusion
- Refusal of valid written consent.
- Insufficient English skills for consenting or interviews.
- Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner.
- Contraindications to MRI scanning, ferrous metal in the body including intracranial, intraorbital, or intraspinal metal, pacemakers, cochlear implants or other non-MRI-compatible devices.
- History of head injury with loss of consciousness for more than 2 minutes, neurological illness, or history of neurosurgical procedures.
- Current DSM-5 diagnosis of any other substance use disorder except Nicotine Use Disorder.
- Current DSM-5 psychotic, mood, anxiety, obsessive-compulsive, trauma-related, or eating disorder, as assessed by SCID-5.
- Current suicidal ideation or homicidal ideation.
- Current use of any psychoactive medication, as evidenced by self-report and UDS.
- History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self-report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar).
- Clinically significant medical problems such as cardiovascular, renal, gastrointestinal, or endocrine problems, as evidenced by medical history and physical exam.
- Past alcohol-related medical illness, such as gastrointestinal bleeding, pancreatitis, or peptic ulcer.
- Current or past hepatocellular disease, as indicated by verbal report or elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 3 times the upper limit of the normal range at screening.
- Females of childbearing potential who are pregnant (by plasma or urine HCG), nursing, or who are not using a reliable form of contraception.
- Current charges pending for a violent crime (not including DUI-related offenses).
- Currently incarcerated.
- Lack of a stable living situation.
- History of head injury with loss of consciousness for more than 2 minutes, neurological illness, or history of neurosurgical procedures.
- Decisionally challenged.
Key Trial Info
Start Date :
October 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04066192
Start Date
October 30 2020
End Date
August 31 2025
Last Update
November 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States, 80045